Article Text

Download PDFPDF
Simultaneous carcinoma of the endometrium and ovary vs. endometrial carcinoma with ovarian metastases: A clinical and immunohistochemical determination
  1. L. Habler,
  2. R. Halperin*,
  3. S. Zehavi,
  4. E. Hadas,,
  5. I. Bukovsky* and
  6. D. Schneider*
  1. * Department of Obstetrics & Gynecology Assaf Harofe Medical Center, Zerifin, Israel
  2. Department of Pathology, Assaf Harofe Medical Center, Zerifin, Israel
  3. Science Based Industrial Park, Ness Ziona, Israel
  4. Science Based Industrial Park, Ness Ziona, Israel
  1. Address correspondence and reprint requests to: Dr R. Halperin, Department of Obstetrics & Gynecology, Assaf Harofe Medical Center, Zerifin 70300, Israel.


The aim of this study was to perform a clinical and immunohistochemical comparison between simultaneous independent tumors involving endometrium and ovary and metastatic endometrial tumors, and to try to find clinical and /or immunohistochemical parameters differentiating between these two entities. Sixteen cases of simultaneous independent primaries of endometrium and ovary, presenting the same histologic type, were compared with 12 cases of primary endometrial cancer, demonstrating ovarian metastases. The comparison related to patients' characteristics and immunohistochemical expression of estrogen and progesterone receptors (ER,PR), bcl-2, HER-2 /neu, p53, and cell proliferation marker Ki-67 in endometrial and ovarian tumors.

The only clinical parameter differentiating significantly between the groups was the prevalence of familial cancer, being more frequent in the group of metastatic tumors (P = 0.03). Immunohistochemical analysis demonstrated the same immunostaining in endometrium and ovary for all immunohistochemical parameters in cases of metastatic endometrial cancer. Conversely, 62.5% of cases with simultaneous tumors of endometrium and ovary could be differentiated from metastatic tumors by distinct immunohistochemical expression of ER and PR in endometrial and ovarian tumors (P = 0.0006), and 31.3% of cases could be differentiated by distinct immunostaining for bcl-2 (P = 0.03). Immunohistochemical parameters HER–2 /neu, p53 and Ki-67 were not appropriate for the distinction between the two study groups. We conclude that the application of immunohistochemical analysis may play an important role in the differentiation between cases of simultaneous independent carcinomas of endometrium and ovary vs. cases of endometrial carcinoma with ovarian metastases.

  • immunohistochemical analysis
  • metastatic endometrial carcinoma
  • simultaneous carcinoma of endometrium and ovary

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.